NEXT SCIENCE LIMITED (NXS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NXS

NXS - NEXT SCIENCE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.12

20 Feb
2025

0.000

OPEN

$0.12

0.000

HIGH

$0.12

0

LOW

$0.12

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-10.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.4 M
Book Value Per Share xxxxxxxxxxxxxxx6.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-22.7 M
Net Profit Margin xxxxxxxxxxxxxxx-73.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-160.01 %
Return on Invested Capital xxxxxxxxxxxxxxx-148.27 %
Return on Assets xxxxxxxxxxxxxxx-109.91 %
Return on Equity xxxxxxxxxxxxxxx-160.01 %
Return on Total Capital xxxxxxxxxxxxxxx-142.67 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-23.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx14 M
Price To Book Value xxxxxxxxxxxxxxx5.28

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx3.99 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx47 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

06/08/2024

3

Market Weight

$0.27

125.00%

Next Science's 2Q sales fell short of Wilsons forecast as activity levels in the durable medical equipment (DME) business took longer-than-expected to recover following last year's restructure.

More positively, the broker highlights good sales for Xperience, noting GPO contract access and prophylactic adoption are both good signs.

The analysts' target falls to 27c from 34c once new equity capital assumptions are revised, taking into account the potential discount at which funds may need to be raised. Market Weight.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -5.96 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.51 cents.
Access Extra Coverage Research History >

NXS STOCK CHART

FNArena News on NXS

1
Australian Broker Call *Extra* Edition – Jan 28, 2025

Jan 28 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 30, 2024

Oct 30 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 06, 2024

Aug 06 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 07, 2024

May 07 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps